Status:
ACTIVE_NOT_RECRUITING
fMRI in Postural Tachycardia Syndrome
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Postural Tachycardia Syndrome
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Postural tachycardia syndrome (POTS) is one of the most common forms of chronic orthostatic intolerance in the United States. This is a disabling disorder characterized by an excessive increase in hea...
Detailed Description
A randomized, double blind, crossover study will be conducted to determine if there are differences in resting brain structure and blood oxygen perfusion in postural tachycardia syndrome (POTS) compar...
Eligibility Criteria
Inclusion
- Men and women of all races or ethnicity
- Age 18-60
- Healthy volunteers or previously diagnosed with POTS by current consensus criteria (rise in heart rate of at least 30 beats/minute within 10 minutes of standing; absence of orthostatic hypotension defined as a drop in blood pressure greater than 20/10 mmHg within 3 minutes of standing; and presence of daily orthostatic symptoms for at least 6 months such as lightheadedness, dizziness, nausea, and palpitations).
- Healthy participants must have cognitive testing scores within normal range (defined by Stroop word-color test score between 40-70) and be able to tolerate lower body negative pressure.
- POTS participants must have either mild cognitive dysfunction (defined by Stroop word-color t-score \<40 and \>30) or normal cognitive function (defined by Stroop word-color test score between 40-70), and able to tolerate lower body negative pressure.
- Capable of giving informed consent
- Fluent in written and spoken English
Exclusion
- Age \<18 years or \>60 years
- Pregnant or breastfeeding women
- Left handedness
- Require glasses for vision correction (contact lenses are okay)
- Current smokers
- Alcohol or drug abuse
- Recreational drug use (e.g. cannabis, heroin, cocaine)
- Other potential causes for tachycardia (e.g. prolonged bed rest, dehydration)
- Taking selective norepinephrine reuptake inhibitors or stimulant medications within the past 3 months as these may alter cognition
- Unable to tolerate an MRI scanner (e.g. claustrophobia, implanted metal)
- Unable to give or withdraw informed consent
Key Trial Info
Start Date :
February 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04137757
Start Date
February 18 2022
End Date
December 1 2026
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033